奥米替尼异丙酯对比噻吗洛尔治疗青光眼或高眼压患者:两项随机3期试验(SPECTRUM 4和3)
SPECTRUM 4和3为3期随机双盲非劣效研究,评估奥米替尼异丙酯(OMDI)0.002%对比噻吗洛尔0.5%在青光眼或高眼压患者中的降眼压疗效与安全性。OMDI在SPECTRUM 4中达到非劣效,SPECTRUM 3中12个月疗效得以维持;两项研究OMDI眼部不良事件更多,但外观改变相关不良事件率低于噻吗洛尔。
要点
- OMDI 0.002%在SPECTRUM 4中降眼压非劣效于噻吗洛尔0.5%,SPECTRUM 3中12个月疗效维持。
- 两项研究OMDI眼部不良事件更多,但外观改变相关不良事件率低于噻吗洛尔。
- SPECTRUM 3中假晶状体患者黄斑水肿率随OMDI暴露延长而升高。
核心结论
- SPECTRUM 4和3显示OMDI对比噻吗洛尔在青光眼或高眼压患者中3个月降眼压疗效与安全性一致。
- SPECTRUM 3的12个月数据提示OMDI可能对青光眼或高眼压患者具有长期获益。
研究设计与样本
- 两项3期、随机、对照、双盲、非劣效研究,在美国多中心开展。
- SPECTRUM 4纳入成人≥18岁409例,SPECTRUM 3纳入成人≥18岁413例及儿童<18岁13例。
- 成人纳入标准为开角型青光眼或高眼压,眼压≥22 mmHg且≤34 mmHg;儿童纳入标准为儿童青光眼或高眼压。
- 两项研究主要目标均为3个月时OMDI降眼压非劣效于噻吗洛尔;SPECTRUM 3另加9个月OMDI治疗。
- 安全性评估包括眼部和非眼部不良事件。
主要发现
- OMDI降眼压幅度在SPECTRUM 4和3中保持一致(分别为-5.6至-5.9 mmHg与-5.3至-5.7 mmHg)。
- 噻吗洛尔疗效在两项研究中存在差异(SPECTRUM 4为-5.4至-6.1 mmHg,SPECTRUM 3为-6.4至-7.0 mmHg)。
- OMDI在SPECTRUM 4中达到非劣效。
- SPECTRUM 3中12个月治疗疗效得以维持。
- 两项研究OMDI眼部不良事件更多,但外观改变相关不良事件率低于噻吗洛尔。
关键数值与推荐
- OMDI 0.002%与噻吗洛尔0.5%为研究干预药物。
- 成人纳入眼压范围为≥22 mmHg且≤34 mmHg。
- 主要疗效指标为3个月眼压降幅的非劣效性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The SPECTRUM 4 and 3 studies assessed the intraocular pressure (IOP)-lowering efficacy and safety of omidenepag isopropyl (OMDI) 0.002% vs timolol 0.5% in patients with glaucoma or ocular hypertension (OHT). DESIGN: Phase 3, randomized, controlled, double-masked, noninferiority studies. METHODS: Multicenter studies in the US. Inclusion criteria for adults ≥ 18 years (SPECTRUM 4 [N = 409] and 3 [N = 413]) were open-angle glaucoma or OHT, and IOP ≥ 22 mm Hg and ≤ 34 mm Hg; and for pediatric patients < 18 years (N = 13, SPECTRUM 3) were pediatric glaucoma or OHT. The primary objective in both studies was OMDI noninferiority to timolol in reducing IOP (3 months). SPECTRUM 3 included an additional 9 months of OMDI treatment. Safety evaluations were of ocular/non-ocular adverse events (AEs). RESULTS: The IOP-lowering range of OMDI remained consistent in SPECTRUM 4 and 3 (-5.6 to -5.9 vs -5.3 to -5.7 mm Hg, respectively); however, timolol efficacy varied (-5.4 to -6.1 vs -6.4 to -7.0 mm Hg, respectively). OMDI noninferiority was achieved in SPECTRUM 4. Efficacy was maintained with 12-month treatment in SPECTRUM 3. Both studies reported more ocular AEs with OMDI, but lower rates of appearance-altering AEs vs timolol. No new safety concerns were identified. Rates of macular edema in pseudophakic patients increased with prolonged OMDI exposure. CONCLUSIONS: SPECTRUM 4 and 3 demonstrated consistent 3-month IOP-lowering efficacy and safety of OMDI vs timolol in patients with glaucoma or OHT. The 12-month data from SPECTRUM 3 suggest OMDI may have long-term benefits in patients with glaucoma or OHT.
引用
- Bacharach J, Brubaker JW, Evans DG, et al. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3). Am J Ophthalmol. 2024. PMID: 38395329. doi:10.1016/j.ajo.2024.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。